TMCnet News
Michael Baum, MD, Cancer Surgeon and Scientist, Joins Oncology Analytics' Distinguished Academic Advisory BoardPLANTATION, Fla. --(Business Wire)-- Oncology Analytics, Inc. (OA) announced today the appointment of Dr. Michael Baum [MB, ChB, FRCS, MD (hon), FRCR (hon)], Professor Emeritus of Surgery and visiting Professor of Medical Humanities, University College London, to its Distinguished Academic Advisory Board. Michael Baum has held the chairs of surgery at Kings College London, the Institute of Cancer Research and University College London. He has been President of the British Oncology Association and the European Breast Cancer Conference and chairman of the Psycho-social committee of the National Cancer Research Institute. He has been awarded the William McGuire prize at San Antonio Texas, the Charles Gross prize in France, the St. Gallen prize in Switzerland, and the gold medal of the International College of Surgeons for his research on the treatment of breast cancer. Dr. Baum established the first clinical trials centers in the UK, was one of the first to challenge the doctrine of radical matectomy, led the first trial that demonstrated the potential of tamoxifen to prolong life in breast cancer victims and was also the first to describe psychometric instruments to measure quality of life in cancer sufferers. Most recently he led the first trial to demonstrate the equivalence of a single dose of intra-operative radiotherapy with 6 weeks of post-operative treatment. Dr. Baum will assist OA with its ongoing critical evaluation of cancer clinical trial design and the relative value of competing therapeutic approaches. Dr. Baum's clinical opinions will also be available to the thousands of oncologists whose practices OA serves. Additionally, Dr. Baum will contribute to clinical research priorities, assist with position papers and participate in producing OA's peer review publications. About Oncology Analytics, Inc. Oncology Analytics (OA) is nationally accredited by URAC, serving providers and healthplans through its easy-to-use MetisTM prior authorization system and broad, guidelines compliant protocols database, supported by expert medical oncology peer review and related advisory services. Oncology Analytics presents treating oncologists with the most efficacious, least toxic and most cost-responsible treatment options, all supported by strong science and clinical data, to help them get a "faster, better yes" in the required prior authorization processes of payers. OA was recognized by Inc magazine's Inc 500|5000 list as the 18th fastest growing private company in the health sector in 2013. www.oncologyanalytics.com
|
